Compare Realty Income Corp (O) vs Summit Therapeutics Inc (SMMT) Price & Performance

Realty Income (O) trades at $54.17, up 1.54% with a bearish technical signal despite recent dividend payments. The REIT shows strong fundamentals with 92.56% gross margins and 21.23% net income margin, though earnings have missed expectations for three consecutive quarters. Revenue growth continues from $5.3B in 2024 to $5.7B in 2025, while debt-to-asset ratio has increased to 39.93%.

Analysts maintain a cautious outlook with 38% buy ratings and $64.80 consensus target, representing 20% upside potential. Key risks include rising interest rates impacting REIT valuations and consecutive earnings misses. The stock offers income appeal with consistent dividends but faces headwinds from bond yield competition and technical weakness.

Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.

The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.